Literature DB >> 33899329

Caspase-9 acts as a regulator of necroptotic cell death.

Tamás Molnár1,2, Petra Pallagi3, Bálint Tél3, Róbert Király4, Eszter Csoma5, Viktória Jenei1, Zsófia Varga1,2, Péter Gogolák1, Anne Odile Hueber6, Zoltán Máté7, Ferenc Erdélyi7, Gábor Szabó7, Aladár Pettkó-Szandtner8, Attila Bácsi1, László Virág9, József Maléth3, Gábor Koncz1.   

Abstract

Necroptosis is a regulated necrotic-like cell death modality which has come into the focus of attention since it is known to contribute to the pathogenesis of many inflammatory and degenerative diseases as well as to tumor regulation. Based on current data, necroptosis serves as a backup mechanism when death receptor-induced apoptosis is inhibited or absent. However, the necroptotic role of the proteins involved in mitochondrial apoptosis has not been investigated. Here we demonstrated that the stimulation of several death and pattern recognition receptors induced necroptosis under caspase-compromised conditions in wild type, but not in Caspase-9 negative human Jurkat and murine MEF cells. Cerulein-induced pancreatitis was significantly reduced in mice with acinar cell restricted Caspase-9 gene knockout. The absence of Caspase-9 led to impaired association of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3 and resulted in decreased phosphorylation of RIP kinases, but the overexpression of RIPK1 or RIPK3 rescued the effect of Caspase-9 deficiency. Inhibition of either Aurora Kinase A (AURKA) or its known substrate, glycogen synthase kinase 3β (GSK3ß) restored necroptosis sensitivity of Caspase-9 deficient cells, indicating an interplay between Caspase-9 and AURKA-mediated pathways to regulate necroptosis. Our findings suggest that Caspase-9 acts as a newly identified regulator of necroptosis and thus Caspase-9 provides a promising therapeutic target to manipulate the immunological outcome of cell death. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Caspase-9; cell death; inflammation; necroptosis; pancreatitis

Year:  2021        PMID: 33899329     DOI: 10.1111/febs.15898

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  5 in total

Review 1.  Types of necroinflammation, the effect of cell death modalities on sterile inflammation.

Authors:  Anett Mázló; Viktória Jenei; Sára Burai; Tamás Molnár; Attila Bácsi; Gábor Koncz
Journal:  Cell Death Dis       Date:  2022-05-02       Impact factor: 9.685

Review 2.  Caspase-9: A Multimodal Therapeutic Target With Diverse Cellular Expression in Human Disease.

Authors:  Maria I Avrutsky; Carol M Troy
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.988

3.  Alterations in Inflammatory Cytokines and Redox Homeostasis in LPS-Induced Pancreatic Beta-Cell Toxicity and Mitochondrial Stress: Protection by Azadirachtin.

Authors:  Annie John; Haider Raza
Journal:  Front Cell Dev Biol       Date:  2022-06-20

4.  Novel role of macrophage TXNIP-mediated CYLD-NRF2-OASL1 axis in stress-induced liver inflammation and cell death.

Authors:  Yongqiang Zhan; Dongwei Xu; Yizhu Tian; Xiaoye Qu; Mingwei Sheng; Yuanbang Lin; Michael Ke; Longfeng Jiang; Qiang Xia; Fady M Kaldas; Douglas G Farmer; Bibo Ke
Journal:  JHEP Rep       Date:  2022-07-08

5.  Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.

Authors:  Javier Octavio Mejía-Hernández; Dinesh Raghu; Franco Caramia; Nicholas Clemons; Kenji Fujihara; Thomas Riseborough; Amina Teunisse; Aart G Jochemsen; Lars Abrahmsén; Giovanni Blandino; Andrea Russo; Cristina Gamell; Stephen B Fox; Catherine Mitchell; Elena A Takano; David Byrne; Panimaya Jeffreena Miranda; Reem Saleh; Heather Thorne; Shahneen Sandhu; Scott G Williams; Simon P Keam; Ygal Haupt; Sue Haupt
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.